ozenoxacin · Lnhc · NDA 208945
Xepi
Earliest generic entry, as listed
29 Jan 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9180200.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9180200 | product, use U-805 | 29 Jan 2032 |
| US 9399014 | use U-805 | 15 Dec 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208945 · 001 · RLD · discontinued | cream, topical | 1% | 29 Jan 2032 |